Table 4 Natural compounds and ncRNAs targeting HH signaling in cancers
From: Hedgehog signaling in tissue homeostasis, cancers and targeted therapies
Name | Features | HH signaling target | Cancer | Model | Effect |
|---|---|---|---|---|---|
Novel natural compounds | |||||
Berberine517 | GI disease treatment | Gli1, Ptch1 | Primary intracranial MB | In vitro and vivo | Tumor growth reduction (37.5%) |
Cynanbungeigenin C/Cynanbungeigenin D518 | Health care drugs | Gli | MB | In vitro and vivo | Inhibition of cell viability and proliferation |
Thymoquinone519 | Anti-oxidant, anti-tumor | Shh, Gli1 | PCa | In vitro and vivo | Inhibition of cell viability and proliferation |
Anti-aging, anti-tumor | Gli1 | GC | In vitro | Cancer cell invasion and metastasis inhibition | |
Ptch, Smo | PC | In vitro | Inhibition of cell viability and increase in apoptosis rate | ||
Food additives | Gli1 | Malignant glioma | In vitro and vivo | Tumor growth reduction (71.4%) | |
Shh, Smo, Gli1, Gli2 | Lung cancer | In vitro | Inhibition of cell proliferation and increase in apoptosis rate | ||
Shh, Smo, Gli | PC | In vitro | Inhibition of cell EMT, proliferation and migration | ||
Shh, Gli1, Ptch1 | MB | In vitro | Inhibition of cell viability and increase in apoptosis | ||
Anti-oxidant, anti-tumor | Gli1, Smo | Tongue and liver cancer | In vivo | Limiting histological carcinogenesis | |
Ptch1, Smo, Gli1 | Liver cancer | In vivo | Limiting histological carcinogenesis | ||
Smo, Ptch1, Ptch2, Gli | PC | In vitro | Inhibition of cell proliferation and increase in apoptosis | ||
Gli1, Ptch | Chondrosarcoma | In vitro | Inhibition of cell proliferation and increase in apoptosis | ||
Ellagic acid529 | Anti-tumor | Gli1, Gli2 | PC | In vivo | Tumor growth and metastasis reduction (41.2%) |
Saikosaponin B1/Saikosaponin D530 | Anti-tumor | Smo | MB | In vitro and vivo | Inhibition of cell proliferation and tumor growth |
Estrogen-like activity | Smo, Gli1 | BC | In vivo | Tumor growth reduction (68%) | |
Gli1 | PCa | In vivo | Tumor growth reduction (58.3%) | ||
Glabrescione B533 | Gli1, Ptch1 | MB | In vivo | Tumor growth reduction (63.6%) | |
Gli1, Ptch1 | BCC | In vitro | Tumor growth reduction (71.4%) | ||
Silibinin534 | Hepatoprotective drugs | Gli1, Gli2 | RCC | In vivo | Tumor growth reduction (64.9%) |
Inoscavin A535 | Smo | CC | In vitro and vivo | Inhibition of cell proliferation and tumor growth | |
Acoschimperoside P, 2’-acetate536 | Gli1, Ptch1 | PC | In vitro | Inhibition of cancer cell proliferation and migration | |
Apigenin537 | Anti-cancer, anti-viral | Gli1 | PCa | In vitro | Inhibition of cancer cell proliferation and migration |
Baicalein537 | Treatment of paralysis after cerebrovascular disease | Gli1 | PCa | In vitro | Inhibition of cancer cell proliferation and migration |
Betulinic acid538 | Anti-cancer | Gli1, Ptch1 | PC and PCa | In vitro | Inhibition of cancer cell proliferation |
Deguelin539 | Insect poisoning, anti-cancer | Gli1, Ptch1, Sufu | PC | In vitro | Inhibition of cell migration and increased apoptosis |
Germacranolide540 | Gli1 | PC | In vitro | Inhibition of cancer cell proliferation | |
Physalin F & B541 | Anti-inflammatory, immunomodulatory | Gli1, Gli2, Ptch1 | PC | In vitro | Inhibition of cancer cell proliferation |
Sutherlandioside D542 | Anti-cancer | Gli1, Ptch1 | PCa | In vitro | Inhibition of cancer cell proliferation |
Sulforaphene543 | Anti-cancer | Gli1 | BC | In vitro | Cell invasion and metastasis inhibition |
Sulforaphane544 | Anti-oxidant, anti-tumor | Smo, Gli1, Gli2 | PC | In vivo | Tumor weight reduction (45.0%) |
Promote calcium and phosphorus absorption | Gli2 | RCC | In vivo | Tumor growth reduction (81.4%) | |
Gli1 | BCC | In vitro and vivo | Tumor growth reduction | ||
NcRNA | |||||
LncRNA GAS5545 | Sufu | TNBC | In vivo | Increased apoptosis in cancer cells | |
LncRNA EGOT546 | Gli1, Smo, Ptch1, Hhip | BC | In vitro and vivo | Inhibition of cell viability and migration capacity | |
LncRNA LIFR-AS1547 | Sufu | BC | In vitro and vivo | Inhibition of cancer cell proliferation and migration | |
Smo | GC | In vitro | Inhibition of cancer cell proliferation and migration | ||
Gli3 | Bladder cancer | In vitro and vivo | Inhibition of cancer cell proliferation and migration | ||
miR-125b550 | Smo | MB | In vivo | Inhibition of cancer cell proliferation and migration | |
miR-141-3p551 | Gli2 | Osteosarcoma | In vitro and vivo | Inhibition of cancer cell proliferation and increased apoptosis in cancer cells | |
miR-182-5p304 | Gli1, Gli2 | Lung cancer | In vitro | Cell proliferation inhibition and increased sensitivity to cisplatin | |
miR-202552 | Gli2 | Osteosarcoma | In vitro and vivo | Inhibition of cancer cell proliferation and increased apoptosis in cancer cells | |
Gli3 | Cervical cancer | In vitro and vivo | Inhibition of cancer cell proliferation and migration | ||
Gli1 | PCa | In vitro | Inhibition of cancer cell proliferation, metastasis and EMT | ||
miR-205HG555 | Ptch1 | EC | In vitro and vivo | Tumor volume reduction (39.4%) | |
miR-367-3p556 | Gli1, Gli2 | PCa | In vitro and vivo | Inhibition of cancer cell proliferation and migration | |
miR-361-3p557 | Gli1, Gli3 | Retinoblastoma | In vivo | Inhibition of cancer cell proliferation and migration | |
miR-324-3p558 | Gli3 | NC | In vitro and vivo | Inhibition of cancer cell proliferation | |
Smo, Gli1 | MB | In vivo | Inhibition of cancer cell proliferation and migration | ||
Gli1 | Glioma | In vitro | Inhibition of cancer cell survival | ||
Smo, Gli1 | MM | In vitro and vivo | Inhibition of cancer cell proliferation and increased apoptosis in cancer cells | ||
Smo | MB | In vivo | Inhibition of cancer cell proliferation and migration | ||
Smo | Glioblastoma | In vitro and vivo | Inhibition of cancer stem cell self-renewal and stemness | ||
Smo | Osteosarcoma | In vitro and vivo | Inhibition of cancer cell proliferation and migration | ||
Smo | CML | In vitro and vivo | Inhibition of cancer cell proliferation and increased apoptosis in cancer cells | ||
Smo | CRC | In vitro | Inhibition of cancer cell proliferation and migration | ||
Smo | Glioma | In vitro | Inhibition of cancer cell proliferation and migration | ||
miR-431565 | Gli | Papillary thyroid carcinoma | In vitro and vivo | Inhibition of cancer cell proliferation and migration | |
miR-506566 | Gli3 | Cervical cancer | In vitro and vivo | Inhibition of cancer cell proliferation and increased apoptosis in cancer cells | |
miR-584567 | Gli1 | Cervical cancer | In vitro and vivo | Inhibition of cancer cell proliferation and migration | |
miR-873568 | Gli1 | Cervical cancer | In vitro and vivo | Inhibition of cancer cell proliferation, metastasis and EMT | |
miR-873-5p569 | Gli1 | GC | In vitro | Inhibition of cancer cell proliferation and migration | |
miR-1271570 | Smo | MM | In vitro and vivo | Inhibition of cancer cell proliferation and migration | |
